ABSTRACT

Introduction: Ovarian cancer is the deadliest gynecologic malignancy in the United States, and effective therapies for recurrent, advanced, and progressive disease are limited. Mesothelin is known to be expressed in ovarian cancers, and antibody-drug conjugates targeting mesothelin are a promising novel therapeutic agent.

Areas Covered: This article reviews the currently available literature of anti-mesothelin antibody-drug conjugates as a novel treatment for ovarian cancer. Preclinical in vitro and in vivo data as well as clinical results are reviewed for each available agent. Additionally, adverse effects are covered.

Expert Opinion: Anti-mesothelin antibody-drug conjugates and their combination with chemotherapeutic agents have undergone phase II trials with encouraging results and demonstrated favorable adverse effect profiles. Phase III data will be necessary to establish its role in ovarian cancer, particularly in recurrent, advanced, or progressive disease.

摘要

简介：卵巢癌是美国最致命的妇科恶性肿瘤，对复发、晚期和进行性疾病的有效治疗有限。已知间皮素在卵巢癌中表达，靶向间皮素的抗体-药物偶联物是一种很有前途的新型治疗剂。

涵盖的领域：本文回顾了目前可用的关于抗间皮素抗体-药物偶联物作为卵巢癌新疗法的文献。审查了每种可用药物的临床前体外和体内数据以及临床结果。此外，还涵盖了不利影响。

专家意见：抗间皮素抗体-药物偶联物及其与化疗药物的组合已经进行了 II 期试验，结果令人鼓舞，并显示出良好的不良反应。III 期数据对于确定其在卵巢癌中的作用是必要的，特别是在复发、晚期或进行性疾病中。